

CITATION REPORT

List of articles citing

Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results

DOI: PM/9865685

Seminars in Oncology, 1998, 25, 4-9.

Source: <https://exaly.com/paper-pdf/130399625/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
308	Oxaliplatin in ovarian cancer. 1999 , 10, S55-S57		1
307	Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. 1999 , 10, 539-45		37
306	Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials. 1999 , 35 Suppl 1, S14-8		10
305	Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. 1999 , 35, 1338-42		213
304	Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. 1999 , 10, 1311-6		42
303	Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice. 2000 , 11, 579-82		17
302	Oxaliplatin. A platinum compound for colorectal cancer?. 2000 , 8, 201-3		3
301	The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. 2000 , 406, 25-32		206
300	Oxaliplatin-induced damage of cellular DNA. 2000 , 58, 920-7		241
299	The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. 2000 , 5, 250-9		61
298	Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients. 2000 , 36, 2335-43		6
297	1999 Highlights From: 22nd Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas December 8-11, 1999. 2000 , 1, 18-25		
296	2000 Highlights from: 36th Annual ASCO Meeting; New Orleans, LA May 2000. 2000 , 1, 180-185		
295	High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). 2001 , 37, 1000-5		112
294	A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. 2001 , 37, 1006-13		33
293	A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. 2001 , 85, 2293-7		271
292	Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. 2001 , 12, 669-74		11

291	Determinants of prognosis and response to therapy in colorectal cancer. 2001 , 3, 102-8	28
290	Oxaliplatin: a new agent for colorectal cancer. 2001 , 3, 147-55	33
289	An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. 2001 , 115, 786-92	49
288	The solubility of calcium oxalate in tissue culture media. 2001 , 291, 69-73	21
287	Radiation recall with oxaliplatin: report of a case and a review of the literature. 2001 , 13, 55-7	3
286	Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. 2002 , 87, 1210-5	118
285	Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. 2002 , 13, 1072-9	31
284	Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. 2002 , 13, 1479-89	61
283	Clinical significance of prognostic and predictive markers in colorectal cancer. 2002 , 2, 209-16	13
282	Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. 2002 , 13, 1490-6	14
281	Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. 2002 , 25, 354-7	14
280	Oxaliplatin: a review of evolving concepts. 2002 , 20, 246-63	52
279	Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. 2002 , 529, 232-6	60
278	Preferential targeting of apoptosis in tumor versus normal cells. 2002 , 1587, 309-17	33
277	Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. 2002 , 38, 1141-7	10
276	Advanced Colorectal Cancer [Chemotherapeutic Treatment of Unresectable Liver Metastases. 2002 , 34, 341-343	
275	Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. 2002 , 52, 1092-8	93
274	Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. 2002 , 86, 1871-5	24

273	Colorectal cancer: integrating oxaliplatin. 2003 , 4, 405-11	9
272	New oxaliplatin-based combinations in the treatment of colorectal cancer. 2003 , 5 Suppl 3, 1-9	1
271	The evolving role of oxaliplatin in the management of colorectal cancer. 2003 , 5 Suppl 3, 10-9	4
270	The mechanism of action of radiosensitization of conventional chemotherapeutic agents. 2003 , 13, 13-21	209
269	DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. 2003 , 66, 225-37	136
268	Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. 2003 , 66, 551-63	38
267	Platinum-based anticancer agents: innovative design strategies and biological perspectives. 2003 , 23, 633-55	279
266	5-fluorouracil: mechanisms of action and clinical strategies. 2003 , 3, 330-8	3191
265	Predictive markers for colorectal cancer: current status and future prospects. 2003 , 2, 223-30	9
264	Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. 2003 , 14, 383-7	87
263	Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. 2003 , 88, 1942-7	18
262	Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies. 2003 , 14, 1776-82	10
261	A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. 2003 , 14, 304-12	29
260	Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study. 2003 , 14, 145-51	1
259	Taxane containing regimens for metastatic breast cancer. 2003 , CD003366	24
258	Therapeutic Strategies to Improve the Efficacy of Oxaliplatin in Gastrointestinal Tumors. 2004 , 19, 183-189	1
257	A review of oxaliplatin and its clinical use in colorectal cancer. 2004 , 5, 2159-70	79
256	Tailored chemotherapy for colorectal cancer: a new approach to therapy. 2004 , 22, 762-73	14

255	Oxaliplatin. 2004 , 3, 11-2	190
254	Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. 2004 , 91, 1442-6	14
253	Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. 2004 , 5, 377-84	22
252	Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin. 2004 , 12, 4565-73	27
251	A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. 2004 , 91, 344-54	317
250	Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. 2004 , 40, 1812-24	23
249	Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. 2004 , 15, 371-6	30
248	Antitumour antibiotic containing regimens for metastatic breast cancer. 2004 , CD003367	14
247	Taxane containing regimens for metastatic breast cancer. 2005 , CD003366	42
246	Synthesis and structure of new trichloroplatinum E complexes: Reactivity of nitrogen lone-pair versus C=C double bond E electrons in ligands, effect of steric hindrance. 2005 , 690, 4856-4866	11
245	Systemic therapy for colorectal cancer. 2005 , 352, 476-87	925
244	Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. 2005 , 93, 29-34	25
243	Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. 2005 , 146, 1027-39	99
242	Hemolysis and thrombocytopenia following oxaliplatin administration. 2005 , 1, 57-60	2
241	Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells. 2005 , 46, 104-15	44
240	Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. 2005 , 56, 391-9	87
239	Platinum-acridinylthiourea conjugates show cell line-specific cytotoxic enhancement in H460 lung carcinoma cells compared to cisplatin. 2005 , 56, 337-43	24
238	Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease. 2005 , 20, 427-31	73

237	Individualized chemotherapy based on genetic and genomic profiling. 2005 , 1, 91-102	
236	The emerging role of oxaliplatin in the treatment of gastric cancer. 2005 , 17, 656-62	8
235	Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. 2005 , 69, 27-34	23
234	Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 2005 , 46, 1437-40	6
233	Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway. 2005 , 5 Suppl 2, S89-97	
232	The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. 2006 , 11, 665-83	1
231	Recent developments in the systemic therapy of advanced gastroesophageal malignancies. 2006 , 15, 131-53	6
230	Is oxaliplatin the optimal platinum agent in gastric cancer?. 2006 , 4, 10-13	3
229	Advances in chemotherapy for colorectal cancer. 2006 , 4, 808-21	17
228	Recent trends and future perspectives in isolated hepatic perfusion in the treatment of liver tumors. 2006 , 6, 553-65	8
227	Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study. 2006 , 54, 347-52	14
226	Colon cancer and apoptosis. 2006 , 191, 517-26	114
225	Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. 2006 , 27, 992-1002	230
224	Cervical Cancer. 2006 ,	
223	Ovarian Cancer. 2006 ,	
222	Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. 2006 , 29, 490-4	13
221	Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. 2006 , 17, 103-5	19
220	Clinical application of oxaliplatin in epithelial ovarian cancer. 2006 , 16, 1717-32	24

219	The development of platinum compounds and their possible combination. 2006 , 60, 59-75	84
218	Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?. 2006 , 13, 1379-85	68
217	Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. 2006 , 448, 797-804	64
216	The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. 2006 , 71, 1540-50	35
215	Neoadjuvant therapy in the treatment of solid tumors. 2006 , 43, 457-551	
214	Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. 2006 , 6, 42	3
213	Recent advances in management of patients with platinum-refractory testicular germ cell tumors. 2006 , 106, 1217-26	55
212	Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study. 2006 , 70, 273-9	6
211	A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors. 2006 , 71, 190-6	2
210	Pharmacogenomics of colorectal cancer prevention and treatment. 2006 , 24, 630-9	8
209	Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia. 2006 , 2, 527-34	60
208	Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. 2007 , 96, 231-40	40
207	Oxaliplatin in the treatment of colorectal cancer. 2007 , 3, 281-94	18
206	Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. 2007 , 132, 1997-9	40
205	FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. 2007 , 30, 15-20	47
204	Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. 2007 , 245, 195-204	9
203	Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats. 2007 , 101, 909-17	20
202	Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. 2007 , 97, 334-44	31

201	Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. 2007 , 59, 613-20	17
200	Silencing of endo-exonuclease expression sensitizes mouse B16F10 melanoma cells to DNA damaging agents. 2007 , 25, 399-410	1
199	The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. 2007 , 9, 361-7	13
198	The influence of temperature on antiproliferative effects, cellular uptake and DNA platination of the clinically employed Pt(II)-drugs. 2008 , 102, 629-35	55
197	[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options]. 2008 , 22, 16-23	7
196	Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. 2008 , 113, 945-55	55
195	Structural aspects of the anti-cancer drug oxaliplatin: A combined theoretical and experimental study. 2008 , 27, 3567-3574	31
194	Trend in cytotoxic activity of a series of cis-[APtCl ₂] (A=ethylenediamine methylated at different positions) complexes. 2008 , 361, 2803-2814	17
193	DNA Alkylating Agents. 2008 , 139-176	6
192	Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. 2008 , 99, 1050-5	97
191	Assessment of nerve excitability in toxic and metabolic neuropathies. 2008 , 13, 7-26	50
190	ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. 2008 , 8, 50	38
189	Oxaliplatin doublets in non-small cell lung cancer: a literature review. 2008 , 60, 325-31	8
188	Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. 2008 , 62, 344-50	8
187	Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells. 2008 , 179, 63-70	45
186	Systemic treatment of colorectal cancer. 2008 , 134, 1296-310	364
185	Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. 2008 , 8, 319-29	9
184	Systemic and targeted therapy for advanced colon cancer. 2008 , 2, 135-49	43

183	Oxaliplatin-based chemotherapy in the management of colorectal cancer. 2008 , 8, 1223-36	32
182	Targeting the extracellular signature of metastatic colorectal cancers. 2009 , 13, 363-79	5
181	Evolution of nonsurgical therapy for colorectal cancer. 2009 , 6, 108-20	23
180	Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. 2009 , 20, 244-50	44
179	Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. 2009 , 37, 78-95	37
178	Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells. 2009 , 182, 173-82	23
177	Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a childrens oncology group study. 2009 , 115, 1765-75	13
176	QM/MM investigation into binding of square-planar platinum complexes to DNA fragments. 2009 , 14, 1165-74	21
175	Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. 2009 , 63, 433-9	12
174	A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. 2009 , 64, 27-33	8
173	Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. 2009 , 64, 917-24	3
172	ERCC1 codon 118 C->T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. 2009 , 100, 278-83	55
171	Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. 2009 , 100, 1261-6	31
170	On the path to seeking novel radiosensitizers. 2009 , 73, 988-96	33
169	A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. 2009 , 45, 1935-49	77
168	Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. 2009 , 8, 15-21	16
167	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. 2009 , 132, 2712-23	155
166	Pharmacogenetics and biomarkers in colorectal cancer. 2009 , 9, 147-60	19

165	Gemox: a widely useful therapy against solid tumors-review and personal experience. 2010 , 22, 298-303	5
164	Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. 2010 , 11, 33-41	32
163	Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. 2010 , 65, 817-24	67
162	Pilot study of irinotecan/oxaliplatin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. 2010 , 28, 343-9	15
161	A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Childrens Oncology Group study. 2010 , 55, 440-5	41
160	Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. 2010 , 25, 846-52	44
159	Recent advances in combined modality therapy. 2010 , 15, 372-81	28
158	Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. 2010 , 9, 229-37	10
157	Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer. 2010 , 11, 18-24	26
156	[Recent developments of pharmacogenomics in the treatment of colorectal cancers]. 2010 , 68, 233-53	2
155	A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer. 2010 , 28, 865-71	5
154	A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction. 2010 , 28, 833-8	7
153	A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors. 2010 , 49, 245-51	2
152	Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer. 2011 , 72, 219-23	3
151	Systemic Therapy for Colon Cancer. 2011 , 167-183	
150	In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines. 2011 , 167, 273-8	20
149	Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. 2011 , 81, 1319-27	21
148	Oxaliplatin-induced neuropathy in colorectal cancer. 2011 , 2011, 201593	51

147	Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. 2011 , 13, 419-25	30
146	Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. 2011 , 7, 29	98
145	Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. 2011 , 16, 708-16	148
144	Sudden-onset pancytopenia with intracranial hemorrhage after oxaliplatin treatment: a case report and literature review. 2011 , 41, 125-9	10
143	A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer. 2012 , 17, 1429-e47	3
142	Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. 2012 , 23, 075103	17
141	The chemotherapy agent oxaliplatin impairs the renewal of fear to an extinguished conditioned stimulus in rats. 2012 , 227, 295-9	10
140	A poly(L-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery. 2012 , 33, 7182-93	62
139	Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer. 2012 , 11, 151-4	7
138	Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo. 2012 , 81, 273-80	34
137	Phosphorylation of p68 RNA helicase by p38 MAP kinase contributes to colon cancer cells apoptosis induced by oxaliplatin. 2012 , 13, 27	14
136	Network insights on oxaliplatin anti-cancer mechanisms. 2012 , 1, 26	14
135	Colorectal Cancer. 2012 , 86-136	
134	Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. 2012 , 13, 1173-91	18
133	Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research?. 2012 , 83, 353-87	21
132	Synthesis and in vitro antiproliferative activity of platinum(II) complexes with N-monoalkyl 1R,2R-diaminocyclohexane as ligands. 2012 , 55, 297-306	24
131	GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. 2012 , 29, 1421-8	29
130	Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer. 2012 , 29, 2831-7	5

129	A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02. 2012 , 70, 665-72	6
128	Neuromuscular complications. 2012 , 105, 781-803	5
127	Preclinical efficacy and safety assessment of nano-oxaliplatin oral formulation prepared by novel Fat Employing Supercritical Nano System, the FESNS . 2012 , 17, 677-86	4
126	Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. 2012 , 105, 793-9	31
125	Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation. 2012 , 2, 68-73	33
124	Synthesis, in vitro cytotoxicity, and interaction with DNA of platinum(II) complexes with N-monocycloalkyl derivatives of 1R,2R-diaminocyclohexane as carrier ligands. 2012 , 7, 642-9	19
123	Chemotherapy-induced peripheral neuropathy in pediatric cancer patients. 2012 , 19, 9-17	44
122	Antitumor platinum(II) complexes of N-monoalkyl-1R, 2R-diaminocyclohexane derivatives with alkyl groups as hindrance. 2012 , 112, 68-76	27
121	A possible link of oxaliplatin-induced neuropathy with potassium channel deficit. 2012 , 45, 403-11	17
120	Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. 2012 , 30, 258-65	2
119	Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. 2012 , 30, 681-7	35
118	A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. 2013 , 60, 1103-7	12
117	Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. 2013 , 71, 619-26	95
116	Emerging trends in understanding chemotherapy-induced peripheral neuropathy. 2013 , 17, 364	38
115	Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. 2013 , 85, 315-31	20
114	Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. 2013 , 32, 49	13
113	A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. 2013 , 60, 230-6	5
112	Histopathology, Morphology and Immunophenotyping of CLL. 2013 , 71-89	

111	Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. 2013 , 71, 1463-72	31
110	Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. 2013 , 39, 27-43	10
109	A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. 2013 , 23, 1577-82	11
108	Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. 2013 , 108, 457-64	33
107	Intestinal absorption and pancreatic function are preserved in anorexia nervosa patients in both a severely malnourished state and after recovery. 2013 , 21, 247-51	15
106	Reversible Bilateral Blepharoptosis following Oxaliplatin Infusion: A Case Report and Literature Review. 2013 , 99, e216-e219	1
105	A Case of Oxaliplatin-Related Ocular Toxicity. 2014 , 55, 143	2
104	Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy. 2014 , 4, 282-96	8
103	Effects of oxaliplatin on DNA condensation. 2014 , 57, 2114-2120	2
102	Novel oxaliplatin derivatives with 1-(substituted benzyl)azetidione-3,3-dicarboxylate anions. Synthesis, cytotoxicity, and interaction with DNA. 2014 , 11, 115-25	5
101	Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. 2014 , 10, 694-707	175
100	Synthesis, spectroscopic characterization, X-ray structure and electrochemistry of new bis(1,2-diaminocyclohexane)gold(III) chloride compounds and their anticancer activities against PC3 and SGC7901 cancer cell lines. 2014 , 38, 3199-3211	14
99	Antitumor platinum(IV) derivatives of oxaliplatin with axial valproate ligands. 2014 , 140, 72-9	55
98	Raltitrexed-based chemotherapy for advanced colorectal cancer. 2014 , 38, 219-25	21
97	Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. 2014 , 13, 73-80	35
96	The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer. 2015 , 16, 404	11
95	Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. 2015 , 201, 90-9	103
94	Drug response of captured BT20 cells and evaluation of circulating tumor cells on a silicon nanowire platform. 2015 , 67, 370-8	9

93	A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy. 2015 , 9, 67-74	17
92	A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. 2015 , 16, 225-32	17
91	DNA Damaging Drugs. 2015 , 9-112	16
90	Rationale for Integrated Procedures: Cyto-reduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined. 2015 , 107-127	
89	DNA Alkylating Agents. 2015 , 197-241	2
88	Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. 2015 , 185, 1022-32	35
87	Oxaliplatin-induced neuropathy: a tale of two electrolytes. 2015 , 23, 1483-5	1
86	Management of the extravasation of anti-neoplastic agents. 2015 , 23, 1459-71	30
85	Presentation and Diagnosis of Hypersensitivity to Platinum Drugs. 2015 , 15, 15	44
84	Taxane-containing regimens for metastatic breast cancer. 2015 , CD003366	37
83	Biodegradable polymer-platinum drug conjugates to overcome platinum drug resistance. 2015 , 5, 83343-83349	16
82	Synthesis, characterization and theoretical calculations of (1,2-diaminocyclohexane)(1,3-diaminopropane)gold(III) chloride complexes: in vitro cytotoxic evaluations against human cancer cell lines. 2015 , 28, 827-44	13
81	Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?. 2015 , 596, 90-107	245
80	Preparation and evaluation of a novel liposomal formulation of cisplatin. 2015 , 66, 90-5	17
79	Preventive Effects of Bee Venom Derived Phospholipase A ₂ on Oxaliplatin-Induced Neuropathic Pain in Mice. 2016 , 8,	22
78	Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. 2016 , 15, 37-46	23
77	Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study. 2016 , 15, e133-40	33
76	Synthesis, cytotoxicity, and interaction with DNA of platinum(II) complexes of (1R,2R)-N1-2-amyl-1,2-diaminocyclohexane. 2016 , 69, 1653-1662	7

75	Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?. 2016 , 78, 673-83	44
74	Development of a controlled-release drug delivery system by encapsulating oxaliplatin into SPIO/MWNT nanoparticles for effective colon cancer therapy and magnetic resonance imaging. 2016 , 4, 1742-1753	20
73	N-Heterocyclic Carbene-Polyethylenimine Platinum Complexes with Potent in Vitro and in Vivo Antitumor Efficacy. 2016 , 27, 1942-8	24
72	Oxaliplatin-based chemotherapy combined with traditional medicines for neutropenia in colorectal cancer: A meta-analysis of the contributions of specific plants. 2016 , 105, 18-34	16
71	Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. 2016 , 173, 3502-3521	50
70	Molecular dynamics simulation and free energy analysis of the interaction of platinum-based anti-cancer drugs with DNA. 2016 , 15, 1650054	1
69	Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial. 2016 , 12, 159-66	1
68	Toward a better understanding of the oxaliplatin mode of action upon the steric hindrance of 1,2-diaminocyclohexane and its analogue. 2016 , 157, 1-7	9
67	Potential of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin. 2016 , 156, 89-97	43
66	Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. 2016 , 3, 71-81	3
65	Neoadjuvant systemic therapy for patients with gastric cancer: Current concepts and outcomes. 2016 , 1, 25-30	
64	Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study. 2016 , 16, 140	15
63	Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. 2016 , 77, 5-18	39
62	Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: Implications of alternative treatment strategies. 2017 , 39, 1621-1630	10
61	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. 2017 , 128, 1166-1175	32
60	Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer. 2017 , 10, 649-660	11
59	Polymeric micelles for targeted tumor therapy of platinum anticancer drugs. 2017 , 14, 1423-1438	34
58	Nicosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response. 2017 , 16, 300-311	23

57	Comprehensive high-throughput image analysis for therapeutic efficacy of architecturally complex heterotypic organoids. 2017 , 7, 16645	30
56	BGP-15 Protects against Oxaliplatin-Induced Skeletal Myopathy and Mitochondrial Reactive Oxygen Species Production in Mice. 2017 , 8, 137	24
55	Thymidine Metabolism as a Confounding Factor for 3LDeoxy-3LF-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model. 2018 , 59, 1063-1069	4
54	Measurement and thermodynamic modelling of ternary liquid-liquid equilibrium for extraction of (1R,2R)-[1,2-Diaminocyclohexane from aqueous solution with C4C5 alcohols at different temperatures. 2018 , 120, 184-190	8
53	Combination of Oxaliplatin and Vit.E-TPGS in Lipid Nanosystem for Enhanced Therapeutic Efficacy in Colon Cancers. 2018 , 35, 27	2
52	A validated inductively coupled plasma mass spectrometry (ICP-MS) method for the quantification of total platinum content in plasma, plasma ultrafiltrate, urine and peritoneal fluid. 2018 , 152, 39-46	10
51	Supramolecular Chemotherapy: Carboxylated Pillar[6]arene for Decreasing Cytotoxicity of Oxaliplatin to Normal Cells and Improving Its Anticancer Bioactivity Against Colorectal Cancer. 2018 , 10, 5365-5372	62
50	Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. 2018 , 57, 650-658	17
49	Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. 2018 , 68, 77-87	84
48	Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15. 2018 , 175, 656-677	21
47	Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study. 2018 , 17, 31-36	8
46	Electrochemical Skin Conductance as a Marker of Painful Oxaliplatin-Induced Peripheral Neuropathy. 2018 , 2018, 1254602	4
45	Role of Dicer in regulating oxaliplatin resistance of colon cancer cells. 2018 , 506, 87-93	7
44	Interrogation of ethnomedicinal plants for synthetic lethality effects in combination with deficiency in the DNA repair endonuclease RAD1 using a yeast cell-based assay. 2018 , 223, 10-21	1
43	From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles. 2018 , 61, 10996-11020	118
42	Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. <i>Cancers</i> , 2018 , 10, 6.6	21
41	Oxaliplatin effects on the DNA molecule studied by force spectroscopy. 2019 , 5, 055009	2
40	Recent Considerations in the Application of RAPTA-C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies. 2019 , 2, 1900042	32

39	Morphology, Loadability, and Releasing Profiles of CalliSpheres Microspheres in Delivering Oxaliplatin: An Study. 2019 , 18, 1533033819877989	7
38	Tracking Photodynamic- and Chemotherapy-Induced Redox-State Perturbations in 3D Culture Models of Pancreatic Cancer: A Tool for Identifying Therapy-Induced Metabolic Changes. 2019 , 8,	14
37	Investigation of liquid-liquid equilibrium for (1-butanol or 1-pentanol + (R)-trans-Cyclohexane-1,2-diamine + water) ternary systems at 298.2 K to 318.2 K. 2019 , 277, 990-995	7
36	Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer. 2019 , 12,	1
35	Phytochemicals of Cinnamomi Cortex: Cinnamic Acid, but not Cinnamaldehyde, Attenuates Oxaliplatin-Induced Cold and Mechanical Hypersensitivity in Rats. 2019 , 11,	13
34	Comparison of 2D and 3D cell cultures of colorectal adenocarcinoma as models for drug screening. 2019 , 68, 2377-2380	2
33	Upregulation of nuclear-enriched abundant transcript 1 confers oxaliplatin resistance to gastric cancer. 2020 , 44, 446-455	4
32	Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. 2020 , 27, 4348-4359	9
31	Impact of naturopathy, yoga, and dietary interventions as adjuvant chemotherapy in the management of stage II and III adenocarcinoma of the colon. 2020 , 35, 2309-2322	2
30	Monitoring cell endocytosis of liposomes by real-time electrical impedance spectroscopy. 2020 , 412, 6371-6380	1
29	Long non-coding RNAs: Key regulators in oxaliplatin resistance of colorectal cancer. 2020 , 128, 110329	6
28	Rac1b: An emerging therapeutic target for chemoresistance in colorectal cancer. 2020 , 153-171	0
27	Synthesis and anticancer activity of new tetrahydroquinoline hybrid derivatives tethered to isoxazoline moiety. 2020 , 29, 675-689	11
26	A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer. 2020 , 388, 111860	16
25	Platinum accumulation in the brain and alteration in the central regulation of cardiovascular and respiratory functions in oxaliplatin-treated rats. 2021 , 473, 107-120	1
24	Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer. <i>Cancers</i> , 2021 , 13,	6.6
23	Achievements in Thermosensitive Gelling Systems for Rectal Administration. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 4
22	evaluation of dendrimeric formulation of oxaliplatin. 2021 , 26, 750-764	0

21	Contribution of Chemotherapy to the Toxicity of Pelvic Irradiation. 2015 , 87-110	1
20	Oxaliplatin in the Treatment of Colorectal Cancer. 2002 , 525-566	1
19	A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors. 2002 , 63, 213-8	6
18	Dose effects of oxaliplatin on persistent and transient Na ⁺ conductances and the development of neurotoxicity. 2011 , 6, e18469	57
17	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. 2017 , 12, e0182512	14
16	Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids. 2018 , 9, 13009-13022	26
15	Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery. 2020 , 27, 3055-3078	5
14	Effect of tissue factor on invasion inhibition and apoptosis inducing effect of oxaliplatin in human gastric cancer cell. 2012 , 13, 1845-9	5
13	Emerging New Drugs for the Treatment of Human Lymphomas. 2000 , 111-131	
12	Phase II study of oxaliplatin, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as second line therapy. 2006 , 38, 201-5	
11	Pharmacological Background. 2007 , 19-28	
10	In vitro Anti-proliferative Effects of ProLindac[?]a Novel Dach-Platinum-Linked Polymer Compound, as a Single Agent and in Combination with Other Anti-cancer Drugs. 2009 , 41-47	0
9	Pharmacogenetics in Colorectal Cancer. 2010 , 61-86	
8	First-line chemotherapy. 2011 , 18-29	
7	Combinations of Platinum Compounds and Ionizing Radiation. 2006 , 93-101	
6	Post-Marketing Surveillance of a generic Oxaliplatin (Alvoxal) in Iranian Patients with Cancer.. <i>Current Therapeutic Research</i> , 2022 , 96, 100657	2.4 1
5	Neue Zytostatika [?]Trends der Medikamentenentwicklung an der Jahrtausendwende. <i>Acta Chirurgica Austriaca</i> , 2000 , 32, 270	
4	Antibody Conjugated PLGA Nanocarriers and Superparamagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3 2

- 3 Environmental Risk Assessment of Oxaliplatin Exposure on Early Life Stages of Zebrafish (). *Toxics*, **2022**, 10, 4-7 3
- 2 Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward.. *Cancers*, **2022**, 14, 6.6 0
- 1 Anticancer alkylating agents. **2022**, 393-505